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Background and purpose   Primary and dynamically maintained 
periprosthetic bone formation is essential for osseointegration of 
hip implants to host bone. Bone morphogenetic proteins (BMPs) 
play a role in osteoinductive bone formation. We hypothesized 
that there is an increased local synthesis of BMPs in the syno-
vial membrane-like interface around aseptically loosened total 
hip replacement (THR) implants, as body attempts to generate or 
maintain implant fixation.
Patients and methods   We compared synovial membrane-like 
interface tissue from revised total hip replacements (rTHR, n = 
9) to osteoarthritic control synovial membrane samples (OA, n = 
11.  Avidin-biotin-peroxidase  complex  staining  and  grading  of 
BMP-2, BMP-4, BMP-6, and BMP-7 was done.  Immunofluores-
cence staining was used to study BMP proteins produced by mes-
enchymal stromal/stem cells (MSCs) and osteoblasts. 
Results and interpretation   All BMPs studied were present 
in the synovial lining or lining-like layer, fibroblast-like stromal 
cells, interstitial macrophage-like cells, and endothelial cells. In 
OA and rTHR samples, BMP-6 positivity in cells, inducible by 
the  proinflammatory  cytokines  tumor  necrosis  factor-α  and 
interleukin-1β,  predominated  over  expression  of  other  BMPs. 
Macrophage-like cells positive for BMP-4, inducible in macro-
phages by stimulation with particles, were more frequent around 
loosened implants than in control OA samples, but apparently not 
enough to prevent loosening. MSCs contained BMP-2, BMP-4, 
BMP-6, and BMP-7, but this staining diminished during osteo-
genesis, suggesting that BMPs are produced by progenitor cells in 
particular, probably for storage in the bone matrix.
 
Aseptic  loosening  of  total  hip  replacements  (THRs)  is  the 
most common reason for revision operations. Connective tis-
sues surrounding aseptically loosened components have been 
studied since the 1970s to evaluate loosening mechanisms. 
Peri-implant tissues contain wear debris particles and mono-
cyte/macrophages, foreign body giant cells, and granulomas 
embedded  in  connective  tissue  implant  capsule  containing 
collagenous matrix, fibroblasts, blood vessels, and mast cells 
(Willert and Semlitsch 1977). An extended synovial space and 
a special synovial membrane-like lining develop upon loosen-
ing of implants (Schmalzried et al. 1992). Many of the local 
resident and immigrant cells have been shown to be activated 
by using cytokines, growth factors, and other proinflamma-
tory  mediators  as  activation  markers  and  this  activation  is 
considered not to be restricted to bone cement due to the so-
called particle disease (Santavirta et al. 1992, Harris 1994). 
Peri-implant foreign body and osteolytic reactions are medi-
ated by fibroblast- and osteoblast-associated receptor activa-
tor  of  nuclear  factor  kappa  B  ligand  (RANKL,  previously 
known as the osteoclastogenic factor), which activates RANK 
receptor-positive progenitor cells belonging to the monocyte/
macrophage cell lineage to fuse to foreign body giant cells 
and osteoclasts (Mandelin et al. 2003). This insight has greatly 
affected implant development so that metal-on-highly cross-
linked  polyethylene  (MoHXPE),  metal-on-metal  (MoM), 
ceramic-on-ceramic  (CoC),  and  ceramic-on-metal  (CoM) 
bearings have been developed to reduce volumetric wear and 
to mitigate particle-driven chronic foreign body inflammation 
and peri-implant osteolysis.
Less attention has this far been paid to new bone formation, 
which reflects attempts to achieve, maintain, and/or re-estab-
lish osseointegration of the implant in a process that in many 
respects resembles enchondral bone formation and fracture 
healing. This point of view seems particularly pertinent when 
our  understanding  of  osseoconduction  and  osseoinduction 
has increased and trabecular metals, hydroxyapatite, teripa-
ratide, and bone morphogenetic proteins (BMPs) have been 
introduced  as  tools  to  stimulate  new  bone  formation. The 
focus of the present study was on BMPs, because of their 
essential role in new bone formation and their potential in 
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BMPs were first recognized because of the ability of demin-
eralized and lyophilized bone to induce new bone formation 
upon implantation in muscle pouches of rabbits. The current 
name was introduced later, in 1971. BMPs belong to the trans-
forming growth factor-β superfamily of proteins. They have 
been found to be synthesized in skeletal tissues by osteoblasts 
and osteoclasts, but also in many extraskeletal tissues by other 
cells,  including  fibroblasts,  macrophages,  and  endothelial 
cells. They act as growth factors, morphogens, or pleiotropic 
cytokines depending on their spatio-temporal expression and 
target cells. They can affect cell motility and apoptosis. BMPs 
drive the differentiation of mesenchymal stromal (stem) cells 
(MSCs) to bone cells and bone formation. At least BMP-2, 
BMP-4, BMP-6, and BMP-7 have been shown to be osteoin-
ductive. On top of that, the very same BMPs appear to inhibit 
osteoclast differentiation and activation (Lories and Luyten 
2005). At least some BMPs have also been found to stimulate 
osteoclasts, a phenomenon that may be linked to bone remod-
eling. BMP-2 induces osteoclast differentiation and survival 
(Itoh et al. 2001) and stimulates the formation of osteoclasts 
in a dose-dependent manner (Wutzl et al. 2006). BMP-4 has 
stimulatory effects on enzymatic bone resorption of the osteo-
clasts (Mishina et al. 2004). BMP-5 and BMP-6 have been 
found to stimulate osteoclast generation in a biphasic mode 
(Wutzl et al. 2006). BMP-7 induces osteoclastogenesis and 
recruitment of osteoclasts (Hentunen et al. 1995).
Based on these earlier findings and their ability to promote 
fracture healing and bone fusion, we studied the above-men-
tioned osteoinductive BMPs for their eventual presence, cel-
lular localization, and extent of expression in the peri-implant 
synovial  membrane-like  interface  tissue  around  aseptically 
loosened THRs, in control synovial membranes and in MSCs 
and osteoblasts produced from MSCs.
Patients and methods
The study protocol was accepted by the Ethics Committee of the 
Helsinki and Uusimaa Hospital District (5/2000;19.6.2000). 
Periprosthetic synovial membrane-like interface tissue sam-
ples (n = 9) were collected from areas adjacent to osteolytic 
lesions between uncemented implants or methylmetacrylate 
cement mantle and host bone from patients undergoing revi-
sion THR operation due to aseptic loosening (mean age 76 
(68–88) years, 6 women) (Table). No clinical or laboratory 
signs of infection were detected. Indication for the primary 
THR  operation  had  been  osteoarthritis  (OA)  in  7  patients, 
femoral fracture in 1 patient, and rheumatoid arthritis (RA) in 
1 patient. Mean time between the primary and revision opera-
tions was 10 (4–17) years. Control synovial membrane sam-
ples from hip joint capsules were collected from OA patients 
undergoing primary THR (n = 11, mean age 73 (58–82), 8 
women). All samples were fixed in formalin and embedded 
in paraffin.
Immunohistochemistry
5-μm  thick  paraffin  tissue  sections  were  deparaffinized  in 
xylene and rehydrated in a graded ethanol series, and in dis-
tilled water. For antigen retrieval, tissue sections were treated 
with 0.1% pepsin in 10 mM phosphate-buffered 150 mM saline 
(PBS, pH 7.4) containing 0.01 N HCl for 30 min at 37°C, fol-
lowed by three 5-min washes with tap water and three 5-min 
washes with 0.01% Triton X-100 in PBS at room temperature. 
Non-specific binding sites were blocked with a 1:50 dilution 
of normal rabbit serum (Vector Laboratories, Burlingame, CA) 
diluted in 4% bovine serum albumin (BSA) in PBS for 60 min at 
room temperature. Excess serum was blotted away. For immu-
nostaining, tissue sections were incubated in (1) affinity-puri-
fied polyclonal goat IgG to human BMP-2 (sc-6895), BMP-4 
(sc-6896), BMP-6 (sc-7406), or BMP-7 (sc-6899) (Santa Cruz 
Biotechnology, Santa Cruz, CA), all diluted to 2 mg/mL in 4% 
BSA-PBS, at 4°C overnight; (2) 0.01% Triton X-100 in PBS 
for 3 periods of 5 min each; (3) biotinylated rabbit anti-goat 
IgG (Vector Laboratories) for 60 min; (4) 0.01% Triton X-100 
in PBS for 3 periods of 5 min each; (5) endogenous peroxidase 
block solution containing 0.3% H2O2in methanol for 10 min; 
(6) 0.01% Triton X-100 in PBS for 3 periods of 5 min each; (7) 
avidin-biotin-peroxidase complex (Vector Laboratories) for 60 
min; (8) Tris-buffered saline (TBS, pH 7.5); and (9) 0.006% 
H2O2 substrate and 0.023% 3,3 diaminobenzidine tetrahydro-
chloride  chromogen  (Dako  ChemMate  detection  kit;  Dako, 
Glostrup, Denmark) for 150 s. The sections were washed in 
tap water and one of the 2 sections on each microscope glass 
slide was counterstained with hematoxylin and the other one 
was left without counterstain. The sections were dehydrated in 
graded ethanol series, cleared in xylene, and mounted.
As a negative staining control, normal goat IgG (Jackson 
Immunoresearch, West Grove, PA) diluted to 2 mg/mL in 4% 
BSA-PBS was used instead of the primary antibody.
Photography and microscopic grading
Stained tissue sections were analyzed under 400× magnifi-
cation using a light microscope coupled to a digital camera. 
Data for revision total hip replacement patients
Case  Sex  Age  Diagnosis a  Years to  Revised  Method of 
        revision  component(s)  fixation b
1  F  79  OA  13  stem  cemented
2  M  75  Fracture  6  cup,  cemented 
          stem  cementless
3  M  88  OA  16  stem  cemented
4  F  68  OA  16  both  cemented
5  M  78  OA  6  both  cemented
6  F  78  OA  5  cup  cemented
7  F  75  OA  7  stem  cementless
8  F  73  OA  4  stem  cementless
9  F  68  RA  17  cup  cemented
a OA: osteoarthritis; RA: rheumatoid arthritis.
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Microscopic findings were graded as follows: 0 = no BMP-
immunoreactive cells; 1 = only occasional BMP-immunore-
active cells (< 10%); 2 = moderate numbers of BMP-immu-
noreactive cells (10–50%); 3 = many BMP-immunoreactive 
cells (> 50%). Based on their location, arrangement, and mor-
phology, BMP-immunoreactive cells were classified into (1) 
synovial lining cells, (2) spindle-shaped, stromal fibroblast-
like cells, (3) interstitial monocyte/macrophage-like cells, and 
(4) endothelial cells. Intensity of the staining was evaluated 
separately. This evaluation was also based in part on our expe-
rience in the identification of such cells through our extensive 
marker studies on interface tissues (Santavirta et al. 1990a, 
1990b, 1998).
One tissue sample, approximately 5–10 mm × 5–10 mm, 
was available per patient. Immunostained and counterstained 
sections were made sequentially from all tissue sample blocks.
One author (VW) studied each section on 2 occasions with 
1 week between, and recorded the above-mentioned BMP-
immunoreactivity grades. Sometimes there were slight dis-
crepancies between these 2 recordings, and then a third session 
was held to define the final BMP-immunoreactivity grade.
Cell culture
Human passage-4 Poietics MSCs (Lot number 6F4392; Lonza 
Walkersville Inc., Walkersville, MD) were cultured in Poiet-
ics mesenchymal stem cell growth medium according to the 
instructions of the provider (Lonza). The cells were seeded 
onto 6-well plates containing coverslips, at 3,500 cells per cm2. 
For osteogenic differentiation, cells were grown for 14 days in 
low-glucose DMEM containing 0.1 μM dexamethasone, 50 
μM ascorbic acid-2-phosphate, 10 mM β-glycerophosphate 
(Sigma-Aldrich, St. Louis, MO), and 10% fetal calf serum. 
Differentiation of the mesenchymal stromal cells to osteo-
blasts was checked using alkaline phosphatase staining, osteo-
calcin staining, and staining of the bone mineral as described 
in detail elsewhere (Myllymaa et al. 2010).
Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde at room temperature 
for 20 min, washed twice in 10 mM phosphate buffered 150 
mM saline (PBS, pH 7.4) with Triton X100 for 10 min each 
time, followed by incubations in (1) 5% normal donkey serum 
(Jackson ImmunoResearch, West Grove, PA) in PBS contain-
ing 0.1% bovine serum albumin, for 60 min; (2) 10 μg/mL 
goat IgG to human BMP-2, BMP-4, BMP-6, or BMP-7 (Santa 
Cruz Biotechnology) for 60 min; and (3) 10 μg/mL Alexa 
Fluor 568-labeled donkey anti-goat IgG (Molecular Probes, 
Eugene, OR) for 60 min. Before mounting, the nuclei were 
stained with 5 μg/mL 4,6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories) for 5 min. As negative staining control, 
non-immune goat IgG (Jackson ImmunoResearch, Newmar-
ket, Suffolk, UK) was used at the same concentration as but 
instead of the primary antibodies. The cells were observed 
under a light microscope coupled to a digital camera.
Statistics
Medians and 95% CIs for medians of cell density scores are 
presented in Figures 2 and 3. Statistical analysis was done 
using  SPSS  software  for  Windows  version  11.5.  Mann-
Whitney U test was used for comparison of paired variables 
between revision THR and OA groups because the data were 
non-parametric. Wilcoxon signed rank test was used for com-
parison between variables within the revision THR and OA 
groups using 2-tailed tests.
Results
General description of the samples
OA  synovial  tissue  samples  contained  mostly  vascularized 
connective tissue with spindle-shaped fibroblasts. No foreign 
bodies or macrophage infiltrates, foreign body giant cells, or 
granulomas were seen in OA synovial joint capsule samples 
(Figure 1A–D). Samples collected from revision THR patients 
consisted of vascularized connective tissue as above, but with 
infiltrating monocyte/macrophages, foreign body giant cells, 
and occasionally foreign body granulomas. Particles of metal-
lic debris, polarizing polyethylene particles, and/or polymeth-
ylmetacrylate voids were seen in all revision THR samples, 
both in the extracellular space and intracellularly—phagocy-
tozed by macrophages and foreign body giant cells. A syno-
vial lining or a synovial lining-like layer (marked with “s” in 
Figure 1E–H) was found to cover the surfaces of the samples.
Comparison of synovial membrane-like peri-implant 
tissues in revision THR with control synovial mem-
brane in OA
Immunoreactive  BMPs  were  found  in  synovial  linings  or 
lining-like  layers,  fibroblast-like  stromal  cells,  interstitial 
monocyte/macrophage-like cells, and endothelial cells in all 
samples  studied.  However,  the  staining  patterns  were  rela-
tively similar in OA control samples and revision THR sam-
ples (Figure 2), but there was a difference (p = 0.04) in the 
density of BMP-4 positive monocyte/macrophage-like cells, 
which were more frequent in revision THR samples than in 
OA tissue samples. In addition, the staining intensity of the 
BMP-4 positive monocyte/macrophage-like stromal cells was 
stronger in revision THR samples than in OA samples (com-
pare panel B with panel F in Figure 1). 
Comparison of different BMPs
When the data were organized according to different BMPs, 
BMP-6 positive cells were generally more frequent than cells 
that were positive for other BMPs. BMP-7 positive cells were 
the least frequent among the BMPs studied, whereas BMP-2 
and BMP-4 positive cells were usually present at intermedi-
ate frequencies (Figure 3). More specifically, in OA samples 
BMP-6 positive cells were more frequent than cells positive 
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except in the comparison between 
BMP-6 and BMP-2 expression in 
synovial  lining  cells  (p  =  0.06). 
There were no statistically signifi-
cant differences between the fre-
quencies of BMP-2, BMP-4, and 
BMP-7 positive cells.
In  revision  THR  samples, 
BMP-6  positive  cells  were  more 
frequent  than  BMP-7  positive 
cells  in  fibroblast-like  stromal 
cells (mean 2.6 vs. 0.9, p < 0.05), 
macrophage-like  cells  (mean  2.9 
vs. 1.6, p < 0.05) and endothelial 
cells (mean 2.2 vs. 1.3, p < 0.05). 
Furthermore, BMP-4 positive cells 
were more frequent than BMP-7 
positive  cells  in  fibroblast-like 
stromal cells (mean 1.9 vs. 0.9, p 
< 0.05) and macrophage-like cells 
(mean 2.4 vs. 1.6, p < 0.05). Any 
other differences between staining 
results  were  not  statistically  sig-
nificant.
BMPs in MSCs and osteoblasts
Expression  of  BMP-2,  BMP-4, 
BMP-6, and BMP-7 was found in 
Figure 1. Immunolocalization of BMP-2 (A, E), BMP-4 (B, F), BMP-6 (C, G), and BMP-7 (D, H) in con-
secutive sections of synovial membrane from the hip joint of one control osteoarthritis patient (A–D) 
and in consecutive sections of interface tissue surrounding aseptically loosened total hip replacement 
component from the hip joint of one revision-operated patient (E–H). The synovial lining is present 
at the right-hand side of osteoarthritis samples (A–D). A similar synovial lining-like layer present in 
revision total hip replacement samples (E–H) is marked with “s”. Some small arteries and veins are 
marked with an asterisk. No counterstaining; original magnification ×400. Scale bars (panels A and E 
only) represent 10 mm.
Figure 2. Cell density scores for BMP-2, BMP-4, BMP-6, and BMP-7 in 
synovial membrane in osteoarthtritis (white bars) compared to synovial 
membrane-like lining membrane in revision total hip replacement (gray 
bars). Medians and 95% CIs for medians are presented. The difference 
in BMP-4 expression between osteoarthritis and aseptic loosening is 
marked with an asterisk (p = 0.04).
human bone marrow-derived MSCs by immunofluorescence 
staining: as granular, cytoplasmic staining (Figure 4, panels 
A, C, E, and G). In spite of the fact that during the 14-day-
long  MSC-to-osteoblast  culture,  the  number  of  the  cells 
increased through proliferation, osteoblast-rich cell cultures 
still contained less cytoplasmic BMP-immunoreactive gran-
ules (Figure 4, panels B, D, F, and H) than the undifferentiated 
Figure 3. Cell density scores for BMPs (BMP-6, BMP-2, BMP-4, and 
BMP-7) in synovial membrane in osteoarthritis (upper row, white bars) 
and in synovial membrane-like lining membrane in revision total hip 
replacement (lower row, gray bars). Medians and 95% CIs for medians 
are presented. Statistically significant differences (p < 0.05) between 
BMP-6 and other BMP types are marked with an asterisk, and statisti-
cally significant differences (p < 0.05) between BMP-4 and BMP-7 are 
marked with #. 424  Acta Orthopaedica 2010; 81 (4): 420–426
MSC progenitors (Figure 4, panels A, C, E, and 
G). Control staining of MSCs (Figure 4I) and 
of osteoblasts (Figure 4J) using normal, non-
immune goat IgG confirmed the specificity of 
the staining. 
Discussion
Although BMP in human bone and bone cells 
(Kloen  et  al.  2003),  cartilage  (Anderson  et 
al.  2000),  and  synovial  fluid  (Honsawek  et 
al. 2009) has been studied, it appears that the 
published  data  regarding  BMP  expression 
in normal or OA synovial tissues are limited 
to the studies of Bramlage et al. (2006), who 
reported  on  BMP-4  and  BMP-5  expression, 
and of Lories et al. (2003), who reported that 
there is BMP-2, BMP-4, BMP-6, and BMP-7 
(OP-1)  expression  in  synovial  membranes. 
BMP-2  and  BMP-6  mRNAs  were  found  to 
be  Ipresent  most  consistently,  and  Lories  et 
al. (2003) found them to be especially present 
in fibroblast-like synovial cells, and also to a 
lesser  extent  in  monocyte/macrophage-like 
cells. In this respect, our results confirm and 
extend these earlier findings. We have not found 
any earlier reports on the possible presence or 
cellular localization of BMPs in the synovial 
membrane-like  interface  tissue  around  loos-
ening THR implants. We can now report that 
BMP-2, BMP-4, BMP-6, and BMP-7 are all 
present around loosening implants, in synovial 
lining (probably in fibroblast-like type B and 
macrophage-like type A lining cells), stromal 
fibroblast-like  cells,  and  interstitial  macro-
phage-like cells. In addition, we found all these 
BMPs to be expressed in vascular cells.
Apart from the presence and cellular local-
ization, we also graded the extent of BMP-
positive cells in revision THR and compared 
it to that in OA. Activated macrophages start 
to produce BMP-4 (Blom et al. 2004). In par-
ticular, using human cDNA expression arrays, 
polyethylene-stimulated  human  macrophage-
like  cells  have  been  shown  to  synthesize 
BMP-4 (Rader et al. 2002). In accordance with 
these findings, we found that BMP-4 positive 
monocyte/macrophage-like cells can be found 
more  frequently  in  the  synovial  membrane-
like interface membrane around loosened THR 
implants  than  in  the  osteoarthritic  synovial 
membrane.  This  statistically  significant  dif-
ference is not likely to be only a chance find-
Figure 4. Immunofluorescence staining of undifferentiated bone marrow-derived human 
mesenchymal stromal/stem cells (A, C, E, G, and I) and after differentiation for 14 days 
in osteogenic medium (B, D, F, H, and J). Staining for BMP-2 (A, B), BMP-4 (C, D), 
BMP-6 (E, F), and BMP-7 (G, H). Negative control is staining with normal nonimmune 
goat IgG (I, J). Nuclear staining with DAPI is shown to demonstrate the presence of cells 
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ing associated with multiple statistical comparisons, because 
there  is  a  clear-cut,  particle-mediated  pathomechanism  to 
explain the increased number of specifically BMP-4 positive 
monocyte/macrophages around joint implants compared to 
OA joints. Thus, this increased number of BMP-4 express-
ing cells around implants may result from increased mono-
cyte/macrophage cell recruitment (Santavirta et al. 1990a, b) 
coupled with their local activation by wear debris (Lassus et 
al. 1998, Ma et al. 2003). There was no significant difference 
in expression of the other BMPs studied between the study 
groups, which may indicate that they are not affected by par-
ticle-associated disease and loosening of the THR implants. 
Alternatively, they may be similarly affected in both OA and 
in loosening because their involvement has been implicated 
in the development of OA (Zoricic et al. 2003, Blom et al. 
2004, Badlani et al. 2008)
Interestingly, Lories et al. (2003) reported that expression of 
BMP-2 and BMP-6 is upregulated in synovial fibroblast-like 
cells by the proinflammatory cytokines tumor necrosis factor-α 
and interleukin-1β, which are mostly produced locally by acti-
vated macrophages. BMP-2 and BMP-6 were not upregulated 
by  interferon-γ,  which  is  mostly  produced  by  activated  T 
lymphoblasts.  In  contrast,  proinflammatory  lipopolysaccha-
ride was found to lead to a reduction in BMP-2 production in 
human macrophages (Champagne et al. 2002). These differ-
ential effects of wear debris particles and soluble proinflam-
matory factors on fibroblast- and macrophage-like cells may 
explain why the cytokine-inducible BMP-6 stained more inten-
sively (compared to other BMPs) in so many cells in both study 
groups. It has also been reported that BMP-7 is only found in 
lymphoid cells (Detmer et al. 1999), which might explain why 
BMP-7 positive cells were found so infrequently.
BMPs are involved in osteoinduction and fracture healing 
because of the ability of presynthesized BMPs to be deposited 
in the bone matrix and to be released from there during oste-
olysis (Kloen et al. 2003). Such bone matrix deposition sug-
gests that preosteoblastic MSCs and/or osteoblasts themselves 
produce BMPs for these stromal deposits. Furthermore, MSCs 
may also play a role in implant fixation and loosening as poten-
tial osteoblast progenitor cells. We therefore checked whether 
MSCs and osteoblasts produced by osteogenic differentiation 
from MSCs contain BMPs. Both MSCs and osteoblasts con-
tained BMPs, but MSCs more than osteoblasts, suggesting 
that MSCs in particular are a potent source of BMPs. This 
confirms and extends earlier findings. During fracture heal-
ing, osteoblasts have been shown to contain BMP-2, BMP-3, 
BMP-4,  and  BMP-7,  and  also  their  receptors  (BMPR-IA, 
BMPR-IB, and BMPR-II) as well as signs of autocrine and 
paracrine stimulation in the form of pBMP-R-Smads (Kloen 
et al. 2003). During the preparation of this work, Seib et al. 
(2009) published that MSCs produce BMPs, of which BMP-2, 
BMP-4, and BMP-6 were tested for, and that this may explain 
why osteogenic differentiation of MSCs forms their default 
pathway in long-term in vitro culture. Taken together, these 
findings suggest that MSCs and osteoblasts also constitute a 
potential source of BMPs in peri-implant bone. 
There are 2 simple and straightforward but contradictory 
interpretations for the difference in BMP-4 between revision 
THR and control samples. It may be that the particle-induced 
BMP-4 production, although clearly increased, is not able to 
promote osseous differentiation enough to maintain implant 
osseointegration.  However,  BMPs,  including  BMP-4,  have 
also been implicated as stimulants in osteoclast formation, 
activation, and/or function (Mishina et al. 2004). It could be 
that the relatively high degree of BMP-4 expression in revision 
THR interface samples is in part responsible for the enhanced 
activity of osteoclasts, and in fact stimulates peri-implant oste-
olysis rather than osseointegration. Furthermore, BMPs have 
been implicated in many diverse responses and their activ-
ity is affected by their concentration, other growth factors/
cytokines, and mechanical stimuli (for some examples, see 
Cunningham 1992, Zeisberg et al. 2003, Csiszar et al. 2008, 
Meynard et al. 2009), so our findings might also be explained 
by connective tissue growth and by BMP-driven formation of 
interface tissues. It remains to be seen whether the promise of 
BMPs in bone defect filling (Murakami et al. 2003), in-growth 
into porous coating (Bragdon et al. 2003), and fracture healing 
(Govender et al. 2002, Jones et al. 2006) can be used in future 
to improve osseointegration of prosthetic joints.
Some limitations of our study are the small sample size and 
the fact that the histopathological grading was done by only 
one researcher. Probably the best control material for revision 
THR samples would be hip pseudocapsule samples surround-
ing well-fixed total hip replacement implants, but for obvious 
reasons such samples are difficult to get. Synovial joint sam-
ples from osteoarthritic joints or traumatized joints have been 
used in almost all previous studies as control samples. Finally, 
the inter- and intra-sample variation in the histopathology of 
interface tissues is quite high. We therefore used a relatively 
crude ad hoc grading system, which may have reduced the 
sensitivity of the analysis, but it was less likely to lead to false 
results and interpretations due to the topographical variation 
in tissue histology.
VW: study design, histological and statistical evaluation, and writing. EW: 
consultations and help in the practical performance of the study, and writ-
ing. TS: mesenchymal stem cell culture and staining work. YT: study design, 
organization of the work, and writing.
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